Survivors of teenage and young adult cancer are at risk of cerebrovascular events, but the magnitude of and extent to which this risk varies by cancer type, decade of diagnosis, age at diagnosis, and attained age remains uncertain. This is the largest-ever cohort study to evaluate the risks of hospitalization for a cerebrovascular event among long-term survivors of teenage and young adult cancer.
I
mprovements in survival over the last few decades mean that >80% of teenagers and young adults (TYA, 15-39 years of age) diagnosed with cancer can expect to survive at least 5 years from diagnosis. 1, 2 This has resulted in a large population of cancer survivors who may be at increased risk of treatment-related longterm adverse health effects. 3, 4 Notwithstanding this finding, TYA cancer survivors are an understudied population, and little is known about the risks of long-term adverse health outcomes in this group. 5, 6 Previous studies of cancer survivors have observed an increased risk of cerebrovascular events after irradiation of the head, neck, and mediastinum. [7] [8] [9] [10] [11] [12] [13] In addition to treatment, local recurrence and brain metastases are also potential causes of cerebrovascular events in cancer populations.
14 Development of a cerebrovascular event after cancer treatment is a serious and potentially life-threatening adverse event, 15 yet only 1 other largescale population-based study has explored the risk of hospitalization for a cerebrovascular event in individuals diagnosed with cancer between 15 and 39 years of age (n=43 154 1-year survivors). 16 In this Danish study, there was a 30% increased risk of hospitalization for a cerebrovascular event for all survivors combined compared with the general population; however, the risk varied by type of cerebrovascular event and cancer type. The magnitude of the effect of attained age, age at cancer diagnosis, and decade of cancer diagnosis on the risk of specific types of cerebrovascular events (eg, cerebral infarction, cerebral hemorrhage) has not previously been investigated and has often been encompassed within studies of all types of cardiovascular events combined. 9, 16, 17 Within the United Kingdom, the risk of having a cerebrovascular event doubles every decade after 55 years of age. 18 Currently, it is unknown what the risk of cerebrovascular events is in TYA cancer survivors and whether this effect doubles beyond 55 years of age. If this theory holds true for TYA cancer survivors, this could lead to a large population of cancer survivors developing a cerebrovascular event in older age.
To our knowledge, this is the largest study to investigate the risk of hospitalization for specific cerebrovascular events in survivors of all and specific types of cancer diagnosed in individuals 15 to 39 years of age. In addition, this study is the first to investigate whether the risk of hospitalization for a cerebrovascular event varies with attained age, age at diagnosis, and decade of diagnosis.
METHODS TYACSS
The TYACSS (Teenage and Young Adult Cancer Survivor Study) is a large population-based cohort consisting of 200 945 5-year survivors of cancer diagnosed at 15 to 39 years of age between 1971 and 2006 in England and Wales. The cohort was ascertained from cancer registrations recorded by the Office for National Statistics and the Welsh Cancer Registry. Cancer registrations were coded according to the relevant revisions of the International Classification of Diseases (ICD) (topography) and International Classification of Diseases for Oncology (morphology). We mapped all ICD-topography and International Classification of Diseases for Oncologymorphology codes into 15 main cancer types based on the classification of cancers for TYAs. 19, 20 We refined the classification slightly to allow for inclusion of finer groupings of carcinomas (see online-only Data Supplement Table I 
Ascertainment of Cerebrovascular Events From Hospital Episodes Statistics
The inpatient Hospital Episode Statistics (HES) database is a national electronic database of routinely collected data on individual hospital admissions to National Health Service (NHS) and private (if care was commissioned by the NHS) hospitals in England. For this study, HES inpatient data were available
Clinical Perspective
What Is New?
• Teenage and young adult cancer survivors are widely acknowledged to be an understudied population, and little is known about the risks of long-term adverse health outcomes in this group of survivors. • This study is the largest ever to investigate the risk of hospitalization for specific cerebrovascular events among survivors of all and specific types of cancer diagnosed in individuals 15 to 39 years of age.
• In addition, this study is the first to investigate whether the risk of hospitalization for a cerebrovascular event varies with attained age, age at diagnosis, and decade of diagnosis.
What Are the Clinical Implications?
• This study found that survivors of a central nervous system tumor, head and neck tumor, and leukemia are particularly at risk of hospitalization for a cerebrovascular event.
• The absolute excess risk of developing a cerebral infarction among central nervous system tumor survivors increases with attained age, and for head and neck tumor survivors, this excess risk remained high across all ages.
• These groups of survivors should be considered for surveillance of cerebrovascular risk factors and potential pharmacological interventions for cerebral infarction prevention. *Constituting ICD10: I64-Stroke not specified as hemorrhage or infarction (n=454); I67.0-Dissection of cerebral arteries, nonruptured (n=10); I67.1-Cerebral aneurysm, nonruptured (n=98); I67.2-Cerebral atherosclerosis (n=38); I67.4-Hypertensive encephalopathy (n=12); I67.5-I67.8-Other specified cerebrovascular disease (n=399); I67.9-Cerebrovascular disease, unspecified (n=244); I68-Cerebrovascular disorders in diseases elsewhere classified (n=3).
from April 1997 to December 2012. Before linking the survivor cohort by NHS number, date of birth, postcode, and sex to the inpatient HES database, we excluded all Welsh survivors (N=11 099) due to HES being restricted to England only. Individuals were also excluded if they had died or emigrated before the start of the follow-up period (April 1, 1997) (N=10 128) (see online-only Data Supplement Figure I for flowdiagram of exclusions). It was not possible to determine the actual linkage rate of the survivor cohort to the inpatient HES database because not all survivors would have been admitted to hospital within the HES years 1997 to 2012. For the vast majority of survivors, the key linkage identifiers-NHS number, date of birth, postcode, and sex-were available, and it is thus more likely that such survivors would not have been admitted to hospital rather than an actual failure to link the survivor to the correct HES record(s). Of the 179 718 survivors eligible to be linked with HES, 84% (150 942) had at least 1 inpatient admission record in HES.
Each inpatient admission initiates a record in the HES database and contains information on the date of admission, methods of admission and discharge, patient demographics, and ≤20 diagnosis variables containing information on the primary condition, conditions diagnosed during hospital admission, and any preexisting comorbidities. All diagnosis variables are coded using the ICD version 10 (ICD-10) and are coded at the time of hospital discharge by trained clinical coders or clinicians using all available clinical notes. 21 *Multivariable models and P-values are adjusted for cancer diagnosis, sex, age at cancer diagnosis, decade of cancer diagnosis, and attained age.
type of cerebrovascular event more than once, then only the first event was retained for the analysis to ensure that any cerebrovascular event was not counted more than once due to potential duplicate recordings. Individuals who developed a cerebrovascular event within the first 5 years from cancer diagnosis were excluded as time at risk started at 5-year survival. Individuals with a first event recorded as sequelae of cerebrovascular disease (ICD-10: I69), but no previous recorded cerebrovascular event in HES were also excluded because such survivors would most likely have had a previous cerebrovascular event before April 1997. After these exclusions, a cohort of 178 962 five-year survivors remained (see online-only Data Supplement Figure I for flow-diagram of exclusions).
Statistical Analysis
Individuals were followed up for cerebrovascular events from 5-year survival or April 1, 1997, whichever date was most recent. Follow-up ended at the first occurrence of death, emigration, hospitalization for a cerebrovascular event, or study end date (December 31, 2012). Cerebrovascularrelated hospitalization rates for the general population were derived from the entire (anonymized) HES dataset for England (N=13 476 762) by dividing the number of individuals with a hospitalization by the midyear general population estimates 22 for each age (1-year bands), sex, and calendar-year (1-year bands). The accumulated person-years (PY) within each corresponding age, sex, and calendar year stratum in the survivor cohort were multiplied by the general population rates to obtain the expected number of cerebrovascular hospitalizations. Analyses were conducted to investigate the risk of a hospitalization for all cerebrovascular events combined and for specific types of cerebrovascular events. The observed number of hospitalizations for a cerebrovascular event was divided by the number expected from the general population (referred to as a standardized hospitalization ratio [SHR]). 17 The absolute excess risk (AER) is the additional number of hospitalizations for a cerebrovascular event compared with that expected based on general population hospitalization rates. It is calculated as the observed minus the expected number of hospitalizations divided by the PY at risk. The AER has been expressed per 10 000 PY throughout the article. 23 For each cerebrovascular event subtype, SHRs and AERs were stratified by the following factors: cancer diagnosis, sex, age at cancer diagnosis (15- and attained age (20-44/45-49/50-54/55-59/≥60 years).
To investigate the simultaneous effect of these variables on the risk of hospitalization for a cerebrovascular event, multivariable Poisson regression was conducted to derive relative risks (RRs) and excess hospitalization ratios (EHRs). RRs can be interpreted as the ratio of the SHRs adjusted for potential confounders. EHRs can be interpreted as the ratio of the AERs adjusted for potential confounders. 24 Negative binomial regression was preferred to Poisson when the data showed signs of overdispersion (see online-only Data Supplement Table  II for dispersion parameters and regression methods used). A likelihood ratio test was used to test for linear trend of a factor by comparing the log-likelihood of a model including the factor variable of interest (eg, attained age [20-44/45-49/50-54/55-59/≥60 years]), which was coded such that it had the median value of the variable at each level, with the log-likelihood of a model without the factor variable of interest. Cumulative incidence with attained age as the time scale was calculated treating death as a competing risk. A P-value of <0.05 (2-sided test) was taken as statistically significant. All statistical analyses were conducted in Stata statistical software (version 14.1, Stata Corp.).
From here on, "hospitalization for a cerebrovascular event" and "cerebral infarction/occlusion/stenosis" will be referred to as "cerebrovascular event" and "cerebral infarction," respectively.
RESULTS

Cohort Characteristics
In all, 178 962 five-year survivors of TYA cancer were included in the analysis, contributing 1 837 996 PY of follow-up. Characteristics of the cohort can be found in online-only Data Supplement 
Risk of Any Cerebrovascular Event
Survivors experienced a 40% significantly increased risk of developing any cerebrovascular event compared with that expected from the general population (SHR=1.4, 95% confidence interval [CI], 1.3-1.4); corresponding to 4 excess events per 10 000 PY (Table 1) . Female survivors experienced significantly fewer excess cerebrovascular events than male survivors (AER=3 and AER=7, respectively; P heterogeneity <0.001). In terms of age at cancer diagnosis, SHRs for a cerebrovascular event were highest among individuals diagnosed with a cancer at 15 to 19 years of age (SHR=3.6, 95% CI, 3.0-4.2; AER=9), andand there was a significant trend for the SHR to decrease with increasing age at diagnosis (P trend <0.001). The SHR declined significantly with attained age (P trend <0.001), although the P-value for trend for the RR fell just short of significance when evaluated in the multivariable model (P trend =0.086) ( Table 2 ). The AERs remained elevated at all ages, however; the multivariable analysis showed a significant increasing trend in the number of excess cerebrovascular events with increasing attained age-survivors ˃60 years of age had 2-fold the number of excess cerebrovascular events than survivors 20 to 44 years of age (EHR=2.4, 95% CI, 1.5-4.1; P trend <0.001) ( Table 2) .
With regard to TYA cancer type, survivors at the highest risk of developing a cerebrovascular event were central nervous system (CNS) tumor survivors (SHR=4.6, 95% CI, 4.3-5.0; AER=34), head and neck tumor survivors (SHR=2.6, 95% CI, 2.2-3.1; AER=22), and leukemia survivors (SHR=2.5, 95% CI, 1.9-3.1; AER=10). The cumulative incidence of developing a cerebrovascular event by 60 years of age was 9.0%, 6.4%, and 5.1% among CNS tumor, head and neck tumor, and leukemia survivors, respectively, whereas 2.3% was expected (Figure 1a) . Because of the substantially increased risk, further analyses were conducted for CNS tumor, head and neck tumor, and leukemia survivors.
CNS Tumor Survivors
Survivors of all CNS tumor types were at increased risk of developing a cerebrovascular event, particularly survivors of embryonal tumors (SHR=12.9, 95% CI, 8.0-19.7; AER=78) and glial tumors (SHR=10.8, 95% CI, 9.5-12.3; AER=72) ( Table 3 ). The SHR was highest among survivors diagnosed when 15 to 19 years of age (SHR=12.7, 95% CI, 10.1-15.9). However, survivors 35 to 39 years of age at diagnosis were still at 3.5-fold increased risk (SHR=3.5, 95% CI, 3.0-4.0). The SHR declined with increasing attained age but remained elevated among all ages (P trend <0.001). In contrast, the AER increased with attained age (P trend <0.001), reaching 55 additional hospitalizations per 10 000 PY within individuals ≥60 years of age ( Figure 2 and Table 3 ).
Head and Neck Tumor Survivors
Male survivors of a head and neck tumor had a significantly greater AER for a cerebrovascular event than female survivors (P trend =0.002), with an excess of 30 events compared with 11 per 10 000 PY, respectively ( Table 4 ). The AER remained significantly increased for all ages; however, the multivariable analysis showed that the AER did not increase significantly with attained age (P trend =0.071) (Figure 3 and online-only Data Supplement Table IV) .
Leukemia Survivors
Survivors of all types of leukemia were at an increased risk of developing a cerebrovascular event, and risk did not depend on the type of leukemia (P heterogeneity =0.130) ( Table 5 ). Leukemia survivors diagnosed at 15 to 19 years of age had the greatest SHR (SHR=5.1, 95% CI, 2.8-8.6), and the SHR decreased significantly with older age at diagnosis (P trend =0.007). The AER increased significantly with attained age until 55 years of age (P trend =0.014), reaching 20 additional hospitalizations per 10 000 PY within individuals 50 to 54 years of age.
Risk of a Cerebral Hemorrhage
The SHR for a cerebral hemorrhage was twice that expected (SHR=2.0, 95% CI, 1.8-2.1). The risk of developing a cerebral hemorrhage among survivors diagnosed more recently (1990-2006) was increased ≈4-fold relative to that expected from the general population (SHR=3.7, 95% CI, 2.9-4.7), whereas it was only 20% increased among survivors diagnosed earlier (1971-1979) (SHR=1.2, 95% CI, 1.0-1.4) ( Table 1 ). This increase in risk for the recent treatment decade was further confirmed by the multivariable analysis (P trend =0.005) (online-only Data Supplement Table V ). In terms of attained age, the SHR was highest for survivors ˂45 years of age (SHR=3.6, 95% CI, 3.1-4.2), declined with increasing attained age, and remained significantly elevated for all ages (SHR at ˃60 years of age=1.2, 95% CI, 1.0-1.4) ( Table 2) .
With regard to TYA cancer type, the SHR was highest among survivors of a CNS tumor and leukemia, with an 8-fold (SHR=8.3, 95% CI, 7.2-9.6) and a 5-fold (SHR=5.2, 95% CI, 3.4-7.6) increased risk, respectively ( Table 1 ). The cumulative incidence of developing a cerebral hemorrhage by 60 years of age was 3.4% and 2.0% among CNS tumor and leukemia survivors, respectively, whereas 0.4% was expected (Figure 1b) . Notably, survivors of melanoma were at increased risk of developing a cerebral hemorrhage (SHR=2.0, 95% CI, 1.5-2.6), but they were not at significantly increased risk of any other cerebrovascular event.
CNS Tumor Survivors
The risk of developing a cerebral hemorrhage was significantly elevated among all CNS tumor survivors. Survivors of glial tumors were at greatest risk (SHR=26.2, 95% CI, 21.5-31.6) ( Table 3 ). The SHR and AER of developing a cerebral hemorrhage among CNS survivors diagnosed more recently (1990-2006) was 27-fold increased relative to that expected from the general population (SHR=26.5, 95% CI, 18.6-36.7; AER=20), whereas it was only 4-fold increased among survivors diagnosed earlier (1971-1979) (SHR=4.2, 95% CI, 2.7-6.1; AER=10). This increase in the SHRs and AERs by more recent treatment decade was confirmed by the multivariable analysis (P trend <0.001 and 0.005, respectively) (online-only Data Supplement Table VI) .
Risk of Cerebral Infarction
Overall, survivors had a 50% significantly increased risk of a cerebral infarction compared with that expected (SHR=1.5, 95% CI, 1.4-1.6; AER=2). In terms of age at cancer diagnosis, the SHR and AER for a cerebral infarction was highest among survivors diagnosed at 15 to 19 years of age (SHR=4.3, 95% CI, 3.3-5.4; AER=4) (Table 1) , who had twice the risk of a cerebral infarction than survivors diagnosed at 35 to 39 years of age (RR=0.5, 95% CI, 0.4-0.7) (online-only Data Supplement Table V ). The AER increased with increasing attained age (P trend <0.001) ( Table 2 ). After adjusting for potential confounders, survivors ˃60 years of age had 6-fold the number of excess cerebral infarction than survivors ˂45 years of age (EHR=5.6, 95% CI, 2.9-10.8).
With regard to TYA cancer type, the SHR was highest among survivors of CNS tumors (SHR=4.4, 95% CI, 3.9-5.0), head and neck tumors (SHR=3.5, 95% CI, 2.8-4.4), leukemia (SHR=2.3, 95% CI, 1.5-3.3), and Hodgkin lymphoma (SHR=2.1, 95% CI, 1.8-2.5) (Table 1). The cumulative incidence of developing a cerebral infarction before 60 years of age was 4.2%, 3.6%, 2.3%, and 2.0% among head and neck tumor, CNS tumor, leukemia, and Hodgkin lymphoma survivors, respectively, whereas 0.9% was expected (Figure 1c) .
CNS Tumor Survivors
The risk of developing a cerebral infarction was significantly elevated among all CNS tumor survivors, with the exception of other specified CNS tumor group. Survivors of embryonal tumors (SHR=18.8, 95% CI, 10.0-32.1) and germ cell tumors (SHR=10.5, 95% CI, 3.4-24.6) were at greatest risk ( Table 3 ). The AER was substantially elevated among survivors of embryonal tumors, with 49 excess cerebral infarctions per 10 000 PY (Table 3) . AERs increased sharply with attained age, reaching 26 excess cerebral infarctions per 10 000 PY in survivors ≥60 years of age (P trend <0.001) (Figure 2 and Table 3 ). In terms of absolute risk, every year, ≈0.4% of CNS tumor survivors ˃60 years of age were hospitalized for a cerebral infarction, compared with ≈0.1% in the general population.
Head and Neck Tumor Survivors
Among head and neck tumor survivors, the AER for a cerebral infarction was higher among males than females (AER=22 and AER=7, respectively; P trend <0.001) (Ta- ble 4). The SHR decreased with attained age (P trend <0.001 but remained elevated for all ages. The AER was high for all ages (AER=10-23) but did not vary significantly with attained age (P trend =0.159) (Figure 3 ). In terms of absolute risk, every year, ≈0.2% of head and neck tumor survivors were hospitalized for a cerebral infarction compared with ≈0.06% in the general population.
Risk of Subarachnoid Hemorrhage
The risk of being hospitalized for a subarachnoid hemorrhage among TYA cancer survivors did not differ significantly from that observed in the general population (SHR=1.0, 95% CI, 0.9-1.1; AER=0) (results not shown).
Risk of Other Cerebrovascular Events
Survivors had a 40% significantly increased risk of any other cerebrovascular events compared with that expected (SHR=1.4, 95% CI, 1.3-1.5; AER=2) ( Table V) . The AER increased with increasing attained age, reaching 2 per 10 000 PY after 60 years of age, which was confirmed by the multivariable analysis, where the EHR increased substantially with attained age (P trend <0.001) ( Table 2) . With regard to TYA cancer type, the risk was highest among survivors of a CNS tumor (SHR=5.1, 95% CI, 4.5-5.8; AER=15), head and neck tumors (SHR=2.7, 95% CI, 2.0-3.5; AER=9), and leukemia (SHR=2.6, 95% CI, 1.7-3.8; AER=4) ( Table 1 ). The cumulative incidence of developing an other cerebrovascular event by 60 years of age was 3.3%, 2.2%, and 1.9% among CNS tumor, leukemia, and head and neck tumor survivors, respectively, whereas 0.8% was expected (Figure 1d ).
CNS Tumor Survivors
Among CNS tumor survivors, the SHR and AER for other cerebrovascular events was highest among survivors of embryonal tumors (SHR=20.2, 95% CI, 10.4-35.3; AER=46) and germ cell intracranial tumors (SHR=12.6, 95% CI, 4.1-29.5; AER=23) ( Table 3) . AERs increased substantially with attained age, reaching 36 excess other cerebrovascular events per 10 000 PY in CNS tumor survivors ≥60 years of age (P trend <0.001) (Figure 2 and Table 3 ).
Head and Neck Tumor Survivors
Among head and neck tumor survivors, the AER increased significantly with attained age, reaching 26 excess other cerebrovascular events per 10 000 PY in survivors ≥60 years of age (P trend =0.002) (Figure 3 and Table 4 ).
DISCUSSION Main Findings
In this largest ever study of TYA cancer survivors, we report a 40% increased risk of hospitalization for a cerebrovascular event compared with that expected in the general population. TYA cancer survivors are at 2-fold, 1.5-fold, and 1.4-fold increased risk of a cerebral hemorrhage, cerebral infarction, and other cerebrovascular event, respectively. By 60 years of age, 9%, 6%, and 5% of CNS tumor, head and neck tumor, and leukemia survivors, respectively, had been hospitalized for a cere- brovascular event. Male TYA cancer survivors had a significantly higher number of excess cerebrovascular events compared with female survivors, especially cerebral infarction among head and neck tumor survivors. We found that the excess risk of developing a cerebral infarction among CNS tumor survivors increases significantly with attained age. Beyond 60 years of age, every year, ≈0.4% of CNS tumor survivors can expect to be hospitalized for a cerebral infarction. The excess risk of developing a cerebral infarction among head and neck tumor survivors did not vary with attained age but was consistently high. Every year, ≈0.2% of head and neck tumor survivors can expect to be hospitalized for a cerebral infarction.
Previous Studies
The only other large-scale cohort investigating hospitalization for cerebrovascular disease-a Danish cohort study 16 of 43 153 1-year survivors of TYA cancer (15-39 years of age)-found a significant 1.3-fold increased risk of hospitalization for any cerebrovascular disease for all survivors combined, which is comparable to the 1.4-fold increased risk observed in our study of 178 964 5-year High-grade tumors are more difficult to treat successfully and are likely to recur, and thus it is not inconceivable that, although a greater proportion of these individuals are becoming 5-year survivors, more aggressive treatment and recurrence of the tumor could increase the risk of cerebral hemorrhage.
Recommendations for Prevention of Cerebrovascular Disease
To our knowledge, there are no specific guidelines for stroke prevention among cancer survivors. The American Heart Association/American Stroke Association (AHA/ASA) and Scottish Intercollegiate Guidelines Network (SIGN) guidelines recommend that individuals considered to be at high risk of stroke in the general population (eg, history of coronary heart disease, previous stroke, high blood pressure, and diabetes mellitus) undergo regular blood pressure checks, implement lifestyle modifications (stop smoking and reduce alcohol consumption), and are considered for pharmacological intervention (eg, antihypertensive medication and statins) to reduce the risk of stroke. 34, 35 In this study, the absolute excess risk of cerebral infarction among CNS tumor survivors and other cerebrovascular event among head and neck tumor survivors increased with attained age, resulting in substantial numbers of excess cerebral infarctions and other cerebrovascular event among older survivors. There is evidence suggesting that stroke risk is increased in cancer survivors treated with cranial irradiation in the absence of atherosclerotic risk factors. 8, 12 As previously mentioned, cranial irradiation has been implicated in causing accelerated atherosclerosis, therefore, it could be argued that cranial irradiation is an atherosclerotic risk factor, and patients treated with cranial irradiation should be considered at high risk, such as patients with hypertension and diabetes mellitus. It may not be unreasonable to suggest that TYA CNS tumor and head and neck tumor survivors (likely treated with head and neck irradiation) should be considered for pharmacological interventions even in the absence of other risk factors. A randomized intervention study may be required to ascertain whether and to the extent to which these survivors would benefit from such treatments.
Study Strengths and Limitations
To ascertain cerebrovascular events, most previous studies used questionnaires, which rely on self-report and may suffer from nonresponse or recall bias. A strength of the current study-in addition to the large cohort size-was that the ascertainment of cerebrovascular events was entirely population-based through linkage of the TYACSS cohort with the population-based HES dataset, thereby eliminating potential nonresponse or recall bias. A limitation of our study is the lack of detailed treatment information, particularly the lack of detailed information on treatment with cranial radiotherapy (eg, availability of cumulative radiation dose to the cranium). However, it would not be practically feasible to collect detailed information on treatment for the entire cohort of 178 962 survivors due the destruction of older medical notes in addition to cost and time restrictions. Nested case-control studies would be required to investigate the risks of developing cerebrovascular disease in relation to treatment elements.
Modifiable lifestyle factors such as hypertension, diabetes mellitus, obesity, and smoking may contribute to the elevated risk of cerebrovascular disease among cancer survivors treated with radiotherapy to the head, neck, and mediastinum. 9, 12, 27 However, we cannot confirm this theory because collecting information on lifestyle factors was beyond the scope of this study.
We acknowledge that survivors in this cohort were treated between 1971 and 2006. Thus, the findings presented may not be translatable to individuals treated with newer therapies in recent years (eg, proton beam therapy). Future prospective studies would be needed to investigate risks of cerebrovascular events after newer treatment protocols.
CONCLUSIONS
In this large-scale study investigating cerebrovascular events in TYA cancer survivors, we found that survivors of a CNS tumor, head and neck tumor, and leukemia are particularly at risk of hospitalization for a cerebrovascular event. The excess risk of developing a cerebral infarction among CNS tumor survivors increases with attained age. For head and neck tumor survivors, this excess risk remains high across all ages. These groups of survivors, and in particular males, should be considered for surveillance of cerebrovascular risk factors and potential pharmacological interventions for cerebral infarction prevention.
